A5026143127- Blood Pressure and Hypertension Studies
- Monoclonal and Polyclonal Antibodies Research
- Cardiac Imaging and Diagnostics
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Health Systems, Economic Evaluations, Quality of Life
- Retinal Diseases and Treatments
- Hormonal Regulation and Hypertension
- Inflammatory Bowel Disease
- Acute Myocardial Infarction Research
- Cardiac electrophysiology and arrhythmias
- Chronic Lymphocytic Leukemia Research
- Diabetes Treatment and Management
- Cardiovascular Syncope and Autonomic Disorders
- Atrial Fibrillation Management and Outcomes
- Heart Failure Treatment and Management
- Retinal and Optic Conditions
- Biosimilars and Bioanalytical Methods
- Cardiac Ischemia and Reperfusion
- Diabetes Management and Research
- Retinal Imaging and Analysis
- Colorectal Cancer Treatments and Studies
- Heart Rate Variability and Autonomic Control
- Amyotrophic Lateral Sclerosis Research
- Cardiac Arrest and Resuscitation
Université de Tours
2016-2025
Centre Hospitalier Universitaire de Tours
2016-2025
Inserm
2007-2025
Thion Medical (France)
2020-2024
Institut thématique Immunologie, inflammation, infectiologie et microbiologie
2015-2023
Lithuanian University of Health Sciences
2021
Hôpital Bretonneau
2013-2020
Centre National de la Recherche Scientifique
2010-2019
Les Hôpitaux de Chartres
2017
Clinique Saint-Joseph
2015
Background Standard of care for interstitial lung disease (ILD) with a nonspecific pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one the first-step therapies while rituximab is used rescue therapy. Methods In randomised, double-blind, two-parallel group, placebo-controlled trial ( NCT02990286 ), patients connective tissue disease-associated ILD or idiopathic (with without autoimmune features) and NSIP (defined on pathological integration clinicobiological data NSIP-like...
Infliximab is an anti-tumor necrosis factor monoclonal antibody approved in chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic (PsA), ankylosing spondylitis (AS), Crohn's disease (CD) and ulcerative colitis (UC). pharmacokinetics variable between patients, but influence of the underlying was never assessed. This study aimed at assessing this using a cohort patients monitored single center with same assay. trough concentrations were determined on samples collected...
<h3>Importance</h3> The systemic safety of intravitreal anti–vascular endothelial growth factor (anti-VEGF) medications is still a matter debate. <h3>Objective</h3> This overview systematic reviews evaluates adverse events associated with anti-VEGF treatments in patients neovascular age-related macular degeneration, diabetic edema, or retinal vein occlusion. <h3>Design, Evidence, and Reporting</h3> search PubMed the Cochrane Central Register Controlled Trials database includes meta-analyses...
Systemic safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) is a matter debate and regular updates are necessary.
Objective Tumor necrosis factor inhibitors are effective in reducing inflammation rheumatic diseases but increase the risk of infections. This study was undertaken to investigate relationship between trough serum concentration infliximab (IFX) and a first infection episode. Methods We retrospectively included all patients who started IFX treatment for an approved indication our department. Patients were followed up based on recommended infusion schedules. studied occurrence episode requiring...
Fatal anaphylactic reactions to cetuximab remain a clinical issue, although they are associated with preexisting immunoglobulin E (IgE) directed against the galactose-α1,3-galactose epitope (α3Gal). We aimed compare usefulness of two assays and determine prevalence anti-α3Gal IgE. An IgE assay was developed (70BP assay) compared commercial [bovine thyroglobulin (bTG) assay]. Both were applied cohorts: 299 healthy blood donors 41 patients head neck cancer treated cetuximab, including four...
Rituximab is a monoclonal antibody directed against CD20, which approved in rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts as target-antigen amount, and immunoglobulin G (IgG) serum concentrations on rituximab pharmacokinetics RA patients.In cohort 64 patients who had received repetitive courses rituximab, count, IgG concentration, body surface area, sex disease activity score 28 joints pharmacokinetic parameters was assessed using population...
Bevacizumab shows inter-individual pharmacokinetic variability, with an exposure-response relationship in metastatic colorectal cancer (mCRC) patients. This study explores whether a double dose of bevacizumab, compared to standard dose, increases efficacy mCRC patients treated bevacizumab-based chemotherapy as first-line therapy and who have low initial trough concentration bevacizumab. PHARBEVACOL is multicenter, randomized, double-blind, two-parallel group trial. All will receive bi-weekly...